azacitidine

Overview

Azacitidine is a hypomethylating agent used in hematologic malignancies, especially acute myeloid leukemia (AML) and myelodysplastic syndromes. It is a nucleoside analog of cytidine that becomes incorporated into RNA and DNA, where it interferes with DNA methyltransferase activity and can lead to reduced DNA methylation. Through these effects, azacitidine may alter gene expression programs involved in malignant cell survival, differentiation, and immune signaling.

Clinically, azacitidine is most often used as part of combination therapy rather than as a stand-alone treatment. In recent research, it has been paired with agents such as venetoclax, romidepsin, dexamethasone, and lenalidomide, reflecting its continuing role as a backbone therapy in both myeloid and lymphoid malignancies. It is also being explored in targeted delivery systems and preclinical combination strategies designed to improve efficacy in difficult-to-treat disease, including TP53-mutated AML and other resistant cancers.

Focus of Latest Publications

Recent publications have continued to position azacitidine as a central component of combination regimens in hematologic cancer therapy.

In relapsed or refractory T-cell lymphoma, a phase 1 trial evaluated escalating doses of lenalidomide added to a regimen of romidepsin, azacitidine, and dexamethasone, referred to as RAdR. The study specifically tested whether adding (RS)-lenalidomide could be tolerated and whether the combination could support further development in R/R T-cell lymphoma, including anaplastic large-cell lymphoma. This work reflects interest in combining epigenetic therapy with immunomodulatory and histone deacetylase–directed approaches.

In AML, azacitidine remained a standard comparator and backbone therapy in multiple studies. One multicenter phase II clinical trial assessed the addition of rosuvastatin to venetoclax-azacitidine in older or unfit AML patients, with the stated aim of improving efficacy and safety. The publication framed venetoclax-azacitidine as the standard of care for newly diagnosed unfit AML, underscoring azacitidine’s established role in frontline low-intensity treatment. Another study focused on tolerability and outcomes with serial 28-day cycles of venetoclax in newly diagnosed AML, again describing venetoclax with azacitidine as the standard regimen in this population.

Azacitidine was also investigated in a targeted nanomedicine strategy for TP53-mutated AML. A study on CLL1 polymeric nanoparticles loaded with the PI3K/BRD4 dual inhibitor MDP5 and azacitidine explored whether targeted delivery could address the unmet need in this high-risk disease. The work used C-type lectin domain family 12 member A, a myeloid-associated target, to guide nanoparticle delivery and evaluated the therapeutic potential of combining a novel inhibitor with azacitidine as a standard-of-care hypomethylating agent. This indicates continued interest in improving azacitidine-based therapy for genetically adverse AML, including TP53-mutant disease.

Preclinical studies also examined azacitidine in broader anticancer sensitization contexts. A medicinal chemistry study of bis-triazole-linked benzenesulfonamides reported that lead compounds 2g and 4g significantly enhanced the antiproliferative effects of azacitidine and sorafenib in breast and pancreatic cancer cells under both normoxic and hypoxic conditions. Although azacitidine was not the primary focus, it served as one of the agents whose activity was potentiated by the new compounds, suggesting possible chemosensitizing interactions.

In ovarian cancer, a machine learning-driven framework integrating cell death and senescence signatures linked differential drug sensitivity to azacitidine among other agents. This study used computational tools to prioritize multi-target drug design and immunotherapy optimization, indicating that azacitidine remains relevant in data-driven analyses of therapeutic response even outside its classic hematologic indications.

Across these studies, azacitidine appears in three recurring roles: as a standard hypomethylating backbone in AML, as a partner in multi-agent epigenetic or immunomodulatory regimens for lymphoma, and as a sensitized or model drug in preclinical combination and computational studies. The recurring pairing with venetoclax, dexamethasone, lenalidomide, sorafenib, and novel targeted inhibitors reflects ongoing efforts to deepen responses, overcome resistance, and extend benefit to high-risk molecular subgroups such as TP53-mutated AML.

Key Publications

May A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma. (Blood advances, 2026, PMID 41779512): "In a phase 1 trial, we tested escalating doses of lenalidomide added to romidepsin, azacitidine, and dexamethasone (RAdR) for patients with R/R TCL."
May CLL1 polymeric nanoparticles loaded with PI3K/BRD4 dual inhibitor MDP5 and azacitidine as a novel treatment for TP53 mutated acute myeloid leukemia. (International journal of pharmaceutics, 2026, PMID 41967591): "To address this unmet need, we investigated the therapeutic potential of targeted nanoparticles (NPs) loaded with MDP5 (our novel BRD4/PI3K dual inhibitor) and azacitidine (AZA), a standard-of-care hypomethylating agent."
May Design and Synthesis of Bis-Triazole-Linked Benzenesulfonamides as Selective Carbonic Anhydrase IX/XII Inhibitors with Chemosensitizing Activity. (Journal of medicinal chemistry, 2026, PMID 42059120): "Lead compounds 2g and 4g significantly enhanced the antiproliferative effects of azacitidine and sorafenib in breast and pancreatic cancer cells under both normoxic and hypoxic conditions."
May Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion. (Cancer immunology, immunotherapy : CII, 2026, PMID 42082682): "A multicenter phase II clinical trial (ChiCTR 2500111931) was conducted to evaluate the efficacy and safety of adding rosuvastatin to venetoclax and azacitidine (venetoclax-azacitidine) in older/unfit AML patients."
Apr A machine learning-driven framework integrating cell death and senescence signatures for multi-target drug design and immunotherapy optimization in ovarian cancer. (NPJ precision oncology, 2026, PMID 42034671): "Drug sensitivity analysis linked CDSLS to differential responses to brivanib, azacitidine, and other agents."
Apr Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. (American journal of hematology, 2026, PMID 41685656): "The standard of care for newly-diagnosed unfit patients with acute myeloid leukemia (AML) is venetoclax (VEN) with azacitidine (AZA)."